MedPath

Boehringer Ingelheim USA Corporation

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

Pharmacokinetics, Safety and Tolerability of Tamsulosin Hydrochloride in Children With Voiding Disorders

First Posted Date
2014-10-17
Last Posted Date
2014-10-17
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
48
Registration Number
NCT02266524

Study to Assess the Influence of Three Different α-antagonists and Placebo on the Extent of Weekly Phenylephrine-induced Mydriasis at Three Different Concentrations of Phenylephrine in Healthy Male Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Placebo
First Posted Date
2014-10-17
Last Posted Date
2014-10-17
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
97
Registration Number
NCT02266537

Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Metformin Extended Release Compared With Mono Compound Tablets in Healthy Male and Female

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2014-10-17
Last Posted Date
2017-03-09
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
30
Registration Number
NCT02266472
Locations
🇩🇪

Boehringer Ingelheim Investigational Site, Ingelheim, Germany

Study to Assess the Bioequivalence of Two Batches of Tamsulosin Hydrochloride in Healthy Male Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Flomax®, Norman II facility
Drug: Flomax®, Nishine facility
First Posted Date
2014-10-17
Last Posted Date
2014-10-17
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
30
Registration Number
NCT02266511

Pharmacokinetics of BIBB 515 BS and Effect of Food After Oral Administration in Healthy Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Other: Standard breakfast (40 g fat)
First Posted Date
2014-10-17
Last Posted Date
2014-10-17
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
8
Registration Number
NCT02266498

Metabolism and Pharmacokinetics of [14C]-BIIL 284 BS in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy
First Posted Date
2014-10-17
Last Posted Date
2014-10-17
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
6
Registration Number
NCT02266550

Relative Bioavailability, Pharmacokinetics, Safety and Tolerability of BIIL 284 BS in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: BIIL 284 BS tablet C
Drug: BIIL 284 BS boli
Other: standard breakfast
First Posted Date
2014-10-16
Last Posted Date
2014-10-16
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
16
Registration Number
NCT02265640

Safety, Tolerability and Pharmacokinetics of Increasing Doses of BIIL 284 BS in Adult and Pediatric Cystic Fibrosis (CF) Patients

Phase 1
Completed
Conditions
Cystic Fibrosis
Interventions
Drug: BIIL 284 BS, low dose, adult patients
Drug: BIIL 284 BS, high dose, pediatric patients
Drug: BIIL 284 BS, medium dose, pediatric patients
Drug: BIIL 284 BS, high dose, adult patients
Drug: Placebo
Drug: BIIL 284 BS, low dose, pediatric patients
Drug: BIIL 284 BS, medium dose, adult patients
First Posted Date
2014-10-16
Last Posted Date
2014-10-16
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
45
Registration Number
NCT02265679

Relative Bioavailability, Pharmacokinetics, Safety and Tolerability of BIIL 284 BS in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: BIIL 284 BS tablet C
Drug: BIIL 284 BS WIF tablet
Drug: BIIL 284 BS tablet D
First Posted Date
2014-10-16
Last Posted Date
2014-10-16
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
12
Registration Number
NCT02265653

Relative Bioavailability, Safety and Tolerability of Two Tablet Formulations of BIIL 284 BS

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: BIIL 284 BS tablet C
Drug: BIIL 284 BS Tablet FF
Other: standard breakfast
First Posted Date
2014-10-16
Last Posted Date
2014-10-16
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
16
Registration Number
NCT02265666
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy